-----begin privacy-enhanced message----- proc-type: 2001,mic-clear originator-name: webmaster@www.sec.gov originator-key-asymmetric: mfgwcgyevqgbaqicaf8dsgawrwjaw2snkk9avtbzyzmr6agjlwyk3xmzv3dtinen twsm7vrzladbmyqaionwg5sdw3p6oam5d3tdezxmm7z1t+b+twidaqab mic-info: rsa-md5,rsa, gilkjp6bbqgmb/cittigm1ps0lv0agb14qaglyzcsumcl/ani7gzrokkp2rqxuwr qgabpw7dpftcaeekio4vlq== 0000950157-97-000351.txt : 19970801 0000950157-97-000351.hdr.sgml : 19970801 accession number:		0000950157-97-000351 conformed submission type:	sc 13d public document count:		1 filed as of date:		19970731 sros:			nasd sros:			nyse subject company:	 	company data:	 		company conformed name:			biopsys medical inc 		central index key:			0001010917 		standard industrial classification:	surgical & medical instruments & apparatus [3841] 		irs number:				330578012 		state of incorporation:			de 	filing values: 		form type:		sc 13d 		sec act:		1934 act 		sec file number:	005-47907 		film number:		97649267 	business address:	 		street 1:		3 morgan 		city:			irvine 		state:			ca 		zip:			92718 		business phone:		7144607800 	mail address:	 		street 1:		3 morgan 		city:			irvine 		state:			ca 		zip:			92718 filed by:		 	company data:	 		company conformed name:			johnson & johnson 		central index key:			0000200406 		standard industrial classification:	pharmaceutical preparations [2834] 		irs number:				221024240 		state of incorporation:			nj 		fiscal year end:			1231 	filing values: 		form type:		sc 13d 	business address:	 		street 1:		one johnson & johnson plz 		city:			new brunswick 		state:			nj 		zip:			08933 		business phone:		9085240400 sc 13d 1 amendment no. 1 ===================================================================== securities and exchange commission washington, d.c. 20549 schedule 13d (amendment no. 1)* under the securities exchange act of 1934 biopsys medical, inc. -------------------------------- (name of issuer) common stock, par value $0.001 per share ---------------------------------------- (title of class of securities) 090651 10 0 ----------- (cusip number) michael h. ullmann, esq. johnson & johnson one johnson & johnson plaza new brunswick, nj 08933 (908) 524-0400 ------------------------------------------------------------ (name, address and telephone number of persons authorized to receive notices and communications) july 31, 1997 ----------------------------------------------------------- (date of event which requires filing of this statement) if the filing person has previously filed a statement on schedule 13g to report the acquisition which is the subject of this schedule 13d, and is filing this schedule because of rule 13d-1(b)(3) or (4), check the following box |_|. * this represents the final amendment. (continued on following pages) (page 1 of 4 pages) cusip no. 090651 10 0 13d page 2 of 4 pages --- ----- - --------------------------------------------------------------------- 1 name of reporting person johnson & johnson s.s. or i.r.s. identification no. of above person 22-01024240 - --------------------------------------------------------------------- 2 check the appropriate box if a member of a group * (a)[ ] (b)[ ] - --------------------------------------------------------------------- 3 sec use only - --------------------------------------------------------------------- 4 source of funds * wc, oo - --------------------------------------------------------------------- 5 check box if disclosure of legal proceedings is required pursuant to items 2(d) or 2(e) [ ] - --------------------------------------------------------------------- 6 citizenship or place of organization new jersey - --------------------------------------------------------------------- 7 sole voting power number of none shares -------------------------------------------- beneficially 8 shared voting power owned by each none reporting -------------------------------------------- person with 9 sole dispositive power none -------------------------------------------- 10 shared dispositive power none - --------------------------------------------------------------------- 11 aggregate amount beneficially owned by each reporting person none - --------------------------------------------------------------------- 12 check box if the aggregate amount in row (11) excludes certain shares * [ ] - --------------------------------------------------------------------- 13 percent of class represented by amount in row (11) 0% - --------------------------------------------------------------------- 14 type of reporting person * hc; co - --------------------------------------------------------------------- * see instructions before filling out (page 2 of 4 pages) this amendment no. 1 amends the statement on schedule 13d filed with the securities and exchange commission on june 2, 1997 (the "schedule 13d") by johnson & johnson ("j&j"). this amendment no. 1 is filed with respect to the shares of common stock, par value $0.001 per share (the "issuer common stock"), of biopsys medical, inc. (the "issuer"). unless otherwise defined herein, all capitalized terms shall have the meanings ascribed to them in the schedule 13d. item 5 of the schedule 13d is hereby amended in its entirety to read as follows: item 5. interest in securities of the issuer. the merger (the "merger") of palisades merger corp., a wholly owned subsidiary of j&j, with and into issuer was consummated and became effective on july 31, 1997. the option granted by the issuer to j&j, pursuant to which j&j had the right, upon the occurrence of certain events, to purchase from the issuer up to 1,970,511 shares of issuer common stock (or such other number of shares of issuer common stock as at the time of exercise equaled 19.9% of the then outstanding shares of issuer common stock) for $27.55 per share, terminated at the effective time of the merger. item 6 of the schedule 13d is hereby amended in its entirety to read as follows: item 6. contracts, arrangements, understandings or relationships with respect to securities of the issuer. the stockholder agreement, pursuant to which certain affiliated stockholders of issuer had agreed to vote (or cause to be voted) their shares of issuer common stock (approximately 3,277,114 shares as of may 21, 1997) in favor of the merger, the adoption of the merger agreement and the approval of the terms thereof and each of the other transactions contemplated thereby, terminated at the effective time of the merger. (page 3 of 4 pages) signature after reasonable inquiry and to the best of my knowledge and belief, i certify that the information set forth in this schedule 13d is true, complete and accurate. johnson & johnson july 31, 1997 by: /s/ peter s. galloway ----------------------------- name: peter s. galloway title: secretary (page 4 of 4 pages) -----end privacy-enhanced message----- 